Our broad portfolio consists of multiplex panels that allow you to choose, within the panel, analytes that best meet your needs. On a separate tab you can choose the premixed cytokine format or a single plex kit.
Cell Signaling Kits & MAPmates™
Choose fixed kits that allow you to explore entire pathways or processes. Or design your own kits by choosing single plex MAPmates™, following the provided guidelines.
The following MAPmates™ should not be plexed together:
-MAPmates™ that require a different assay buffer
-Phospho-specific and total MAPmate™ pairs, e.g. total GSK3β and GSK3β (Ser 9)
-PanTyr and site-specific MAPmates™, e.g. Phospho-EGF Receptor and phospho-STAT1 (Tyr701)
-More than 1 phospho-MAPmate™ for a single target (Akt, STAT3)
-GAPDH and β-Tubulin cannot be plexed with kits or MAPmates™ containing panTyr
.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Select A Species, Panel Type, Kit or Sample Type
To begin designing your MILLIPLEX® MAP kit select a species, a panel type or kit of interest.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Species
Panel Type
Selected Kit
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
96-Well Plate
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
Add Additional Reagents (Buffer and Detection Kit is required for use with MAPmates)
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Space Saver Option Customers purchasing multiple kits may choose to save storage space by eliminating the kit packaging and receiving their multiplex assay components in plastic bags for more compact storage.
This item has been added to favorites.
The Product Has Been Added To Your Cart
You can now customize another kit, choose a premixed kit, check out or close the ordering tool.
504187
Sigma-AldrichP2Y Antagonist II, BPTU - CAS 870544-59-5 - Calbiochem
The quantity field is empty. Please enter a quantity of 1 or more to add items to your cart.
Description
Overview
A phenoxypyridinyl-phenylurea that acts as a highly selective P2Y1 antagonist (Ki = 6 nM against 0.5 nM 2-MeS-ADP for human P2Y1 binding), while displaying much reduced or no affinity toward other P2Y family GPCRs (Ki = ≥2.5 µM toward hP2Y14; Ki >15 µM toward human P2Y2, P2Y6, P2Y11, and P2Y12). Effectively inhibits 2.5 µM ADP-induced platelet aggregation in vitro (IC50 = 2.1 µM) and reduces FeCl2-induced carotid artery blood clot formation in anesthetized rats in vivo (10 mg/kg/h i.v. infusion) with much less effect toward prolonging cuticle and mesenteric bleeding time when compared to another P2Y12 antagonist Clopidogrel. Pharmackinetic studies reveal only moderate oral bioavailability in rat.
Catalogue Number
504187
Brand Family
Calbiochem®
Synonyms
Purinergic Receptor P2Y Antagonist II, 1-(2-(2-tert-Butylphenoxy)pyridin-3-yl)-3-(4-(trifluoromethoxy)phenyl)urea
References
References
Zhang, D., et al. 2015. Nature In press. Chao, H., et al. 2013. J. Med. Chem.56, 1704.
Zhang, D., et al. 2015. Nature In press. Chao, H., et al. 2013. J. Med. Chem.56, 1704.
Data Sheet
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
Revision
09-August-2013 JSW
Synonyms
Purinergic Receptor P2Y Antagonist II, 1-(2-(2-tert-Butylphenoxy)pyridin-3-yl)-3-(4-(trifluoromethoxy)phenyl)urea
Description
A phenoxypyridinyl-phenylurea that acts as a highly selective P2Y1 antagonist (Ki = 6 nM against 0.5 nM [β-33P]-2-MeS-ADP in competitive binding assays toward human P2Y1), while displaying much reduced or no affinity toward other P2Y family G-protein-coupled purinergic receptors (Ki = ≥2.5 µM against 0.5 nM [β-33P]-2-MeS-ADP binding toward hP2Y14; Ki >15 µM toward human P2Y2, P2Y6, P2Y11, and P2Y12). Effectively inhibits 2.5 µM ADP-induced platelet aggregation in vitro (IC50 = 2.1 µM using human platelet rich plasma) and reduces FeCl2-induced (via 10 min localized artery surface exposure to 50% FeCl2) carotid artery internal thrombus (blood clot) formation in anesthetized rats in vivo (by 68% 50 min post 10 min FeCl2 exposure; single 10 mg/kg i.v. 15 min prior to FeCl2 exposure, followed by continuous i.v. infusion at 10 mg/kg/h) with only 3.3- and 3.1-fold enhanced cuticle and mesenteric bleeding time, respectively. The same antithrombosis efficacy when achieved with the P2Y12 antagonist Clopidogrel (20 mg/kg p.o.) is reported to result in much prolonged cuticle and mesenteric bleeding time (4.1- and 8.2-fold of control level, respectively). Pharmacokinetic studies in rats indicate a moderate oral bioavailability (F = 10%; Cmax = 5.83 µM; Tmax = 2 h; T1/2 = 1.43 h; 30 mg/kg delivered with 10% cremophor:10% EtOH:80% H2O).
Form
White powder
Intert gas (Yes/No)
Packaged under inert gas
CAS number
870544-59-5
Chemical formula
C₂₃H₂₂F₃N₃O₃
Structure formula
Purity
≥99% by HPLC
Solubility
DMSO (100 mg/ml)
Storage
Protect from light +2°C to +8°C
Do Not Freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity
Standard Handling
References
Zhang, D., et al. 2015. Nature In press. Chao, H., et al. 2013. J. Med. Chem.56, 1704.
